A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

Brandon W. Higgs, Yihong Yao, Chris Morehouse et al.|Annals of the Rheumatic Diseases|2013

Cited by 168